Unknown

Dataset Information

0

Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells.


ABSTRACT: Curative effects of graft-versus-leukemia-based therapies such as donor lymphocyte infusion (DLI) for chronic myelogenous leukemia (CML) may result from immunologic ablation of self-renewing CML progenitor cells. Patients who achieved durable remissions after DLI developed a significant B-cell lymphocytosis after treatment, which did not occur in patients who were unresponsive to DLI. In this study, we identified antigen targets of this B-cell response by probing two immunoproteomic platforms with plasma immunoglobulins from seven CML patients with clinically apparent graft-versus-leukemia responses after DLI. In total, 62 antigens elicited greater reactivity from post-DLI versus pre-DLI plasma. Microarray analysis revealed that >70% of the antigens were expressed in CML CD34(+) cells, suggesting that expression in malignant progenitor cells is a feature common to antibody targets of DLI. We confirmed elevated expression of three target antigens (RAB38, TBCE, and DUSP12) in CML that together consistently elicited antibody responses in 18 of 21 of an additional cohort of CML patients with therapeutic responses, but not in normal donors and rarely in non-CML patients. In summary, immunologic targets of curative DLI responses include multiple antigens on CML progenitor cells, identifying them as potential immunogens for vaccination and/or monitoring of immunotherapeutics designed to eliminate myeloid leukemia stem cells.

SUBMITTER: Biernacki MA 

PROVIDER: S-EPMC2832197 | biostudies-literature | 2010 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells.

Biernacki Melinda A MA   Marina Ovidiu O   Zhang Wandi W   Liu Fenglong F   Bruns Ingmar I   Cai Ann A   Neuberg Donna D   Canning Christine M CM   Alyea Edwin P EP   Soiffer Robert J RJ   Brusic Vladimir V   Ritz Jerome J   Wu Catherine J CJ  

Cancer research 20100126 3


Curative effects of graft-versus-leukemia-based therapies such as donor lymphocyte infusion (DLI) for chronic myelogenous leukemia (CML) may result from immunologic ablation of self-renewing CML progenitor cells. Patients who achieved durable remissions after DLI developed a significant B-cell lymphocytosis after treatment, which did not occur in patients who were unresponsive to DLI. In this study, we identified antigen targets of this B-cell response by probing two immunoproteomic platforms wi  ...[more]

Similar Datasets

| S-EPMC3150287 | biostudies-literature
| S-EPMC2440422 | biostudies-literature
| S-EPMC2775681 | biostudies-other
| S-EPMC7782553 | biostudies-literature
| S-EPMC3220886 | biostudies-other
| S-EPMC7312032 | biostudies-literature
| S-EPMC3307705 | biostudies-literature
| S-EPMC10616083 | biostudies-literature
| S-EPMC8582551 | biostudies-literature
| S-EPMC5834470 | biostudies-literature